Pharmacokinetics and pharmacodynamics of bromocriptine in the rat
✍ Scribed by H. F. Schran; F. L. S. Tse; S. I. Bhuta
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 515 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
✦ Synopsis
The absorption, distribution, and excretion of bromocriptine were studied following oral and parenteral administration of non-radioactive and "C-labelled drug in the rat. Total radioactivity was measured in blood, tissues, and excreta by liquid scintillation counting while the parent drug was determined in plasma and selected tissues by radioimmunoassay. The pharmacokinetic observations were compared with the time course of drug-induced hypothermia in cold-room acclimatized rats. The results indicated that oral doses of bromocriptine were rapidly, though incompletely (32-40 per cent), absorbed, but underwent extensive first-pass metabolism, resulting in an absolute bioavailability of only 6 per cent. The bioavailability increased to approximately 22 per cent in rats pretreated with the hepatic microsome inhibitor proadifen, thus suggesting the liver as the principal site of biotransformation. Absorbed bromocriptine showed preferential distribution into the tissues, although no apparent accumulation of drug-related material occurred in the body. The drug was eliminated almost exclusively by metabolism and biliary excretion into the faeces. Comparison of the pharmacodynamic and the pharmacokinetic profiles indicated a dose relationship between hypothermia and plasma bromocriptine concentrations but not total radioactivity levels. The hypothermic response was also intensified by proadifen pretreatment, thus confirming the parent drug as the pharmacologically active entity. It is believed that the previously reported delay in the onset of bromocriptine activity is not pharmacokinetic in nature, but is related to the properties of the receptors at the target site or to the pharmacologic events that result in the observed effects.
KEY WORDS Bromocriptine Pharmacokinetics Pharmacodynarnics Rat
Introduction
Bromocriptine (2-bromo-alpha-ergocryptine, ParlodeP) is a semisynthetic ergot alkaloid drug of the ergopeptine series. Experimental evidence suggests that many of the neuroendocrine, central, and cardiovascular effects of
📜 SIMILAR VOLUMES
The distribution, metabolism, and pharmacokinetics of physostigmine (Phy) and the time course of butyrylcholinesterase (BuChE) in plasma and cholinesterase (ChE) activity in brain and muscle and their relationship to Phy concentration were described after oral administration of 3H-Phy (650pg kg-') t
Tissue distribution and pharmacodynamics of verapamil were evaluated during steady state intravenous (i.v.) infusion and after single dose intraperitoneal (i.p.) drug administration to female Sprague-Dawley rats. In one group of rats, verapamil was infused to a steady state concentration at which ti
Gender differences in pharmacokinetics and pharmacodynamics of azosemide were evaluated after intravenous, 10 mg kg -1 , and oral, 10 mg kg -1 , administration to male and female rats. After intravenous administration to male rats, the percentages of intravenous dose of azosemide recovered from enti